Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-20 · accession 0001193125-26-064151 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-23 | 2026-02-20 | ANTX | Easom Eric | CEO, Dir | A - Grant | $0.00 | +112.2K | 368.6K | +44% | $0 |
| D | 2026-02-23 | 2026-02-20 | ANTX | Easom Eric | CEO, Dir | A - Grant | $0.00 | +224.5K | 224.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-20 | A | A | 112,250 | $0.00 | 368,630 | D | — | — | (F1) Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. (F2) Includes a balance of (i) 145,250 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025 and (ii) 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2026-02-20 | A | A | 224,500 | $0.00 | 224,500 | D | $1.04 · — to 2036-02-19 | 224,500 Common Stock | (F6) The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. |